Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could sharpen detection of aggressive breast cancer

NCT ID NCT06203119

Recruiting now Diagnosis Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests a new radioactive tracer called 68Ga-DOTA-BPP, which targets a protein (ACE) found on some cancer cells. Researchers want to see if it can improve PET/CT imaging for people with triple-negative breast cancer, a type that can be harder to detect. The trial involves 20 participants and will compare the new tracer's images with standard scans and lab results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive tracer called 68Ga-DOTA-BPP, given as an injection before PET/CT imaging
What this could lead to
If successful, this imaging method could provide a more precise way to detect and stage triple-negative breast cancer, potentially guiding better treatment decisions.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. The tracer's effectiveness and safety are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer disease neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ethics Committee of Peking University Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.